Oritavancin and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cariprazine
Oritavancin
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Cariprazine (Vraylar) is broken down and turned into its active forms by a liver enzyme called CYP3A4. Oritavancin is an antibiotic that can gently nudge that same enzyme to work faster. Because this speeds up the enzyme, it could change how much cariprazine your body has at any time. The tricky part is that CYP3A4 both makes and clears cariprazine's active pieces, so the net effect has not really been studied.
Please don't worry or change anything on your own. This is a theoretical concern, and your care team can plan for it by watching how you respond and adjusting your dose if needed. Just make sure your pharmacist and doctor know you take both.
Mechanism: Cariprazine is a CYP3A4 substrate whose active metabolites (desmethyl- and didesmethyl-cariprazine) are both formed and eliminated by CYP3A4. Oritavancin is a weak CYP3A4 inducer, so the net effect on total active-moiety exposure is unpredictable.
- Direction: Uncertain. Induction could lower parent cariprazine but shift active-metabolite balance; overall exposure not characterized.
- Evidence: Theoretical; not formally evaluated.
- Onset: Unspecified.
- Management: Coadministration is not recommended per labeling. If unavoidable, monitor for altered antipsychotic efficacy and for adverse effects (akathisia, EPS, sedation); individualize dosing.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
Using cariprazine (which is a CYP3A4 substrate) together with a CYP3A4 inducer is not advised. The generation and clearance of cariprazine's active metabolites depend on CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall effect remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
First, keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Do not stop or adjust anything on your own.
- Let your pharmacist and prescriber know you are taking cariprazine and oritavancin together, since guidance advises against pairing them.
- Your care team may watch you more closely for changes in how well the cariprazine is working, or for side effects like restlessness, muscle stiffness, or drowsiness.
- Your dose may need to be adjusted and individualized by your care team.
- Report any new or worsening symptoms promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Oritavancin and Cariprazine together?
Combining cariprazine and oritavancin is not recommended because oritavancin may alter cariprazine levels in an unpredictable way; keep taking both as prescribed and ask your pharmacist or doctor to review the combination and watch how you respond. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Oritavancin and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Oritavancin and Cariprazine interaction managed?
First, keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Do not stop or adjust anything on your own. Let your pharmacist and prescriber know you are taking cariprazine and oritavancin together, since guidance advises against pairing them. Your care team may watch you more closely for changes in how well the cariprazine is working, or for side effects like… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Oritavancin or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Cariprazine
Keep reading about Oritavancin
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist